Company Announcements and Press Releases

Novo Nordisk country sites USA Argentina Australia Austria Belgium Brazil Bulgaria Canada Chile China Croatia Czech Republic Denmark Egypt Estonia Finland France Germany Greece Hungary India Iraq Ireland Israel Italy Japan Korea (Republic) Latvia Lebanon Lithuania Mexico Netherlands New Zealand Norway Pakistan Poland Portugal Romania Russian Federation Serbia Slovak Republic Slovenia South Africa Spain Sweden Switzerland Syria Taiwan Thailand Turkey Ukraine United Kingdom Other Novo Nordisk sites Changing diabetes NovoMedLink DAWN study Hagedorn Research Institute Diabetes4Patients Diabetes Barometer Changing diabetes bus Media prize World diabetes day School challenge Improve Control HRT for HCPs HRT for women HRT congresses & symposia

• News
• Facts about Novo Nordisk
• R&D pipeline
• Download centre
• Diabetes dictionary
• Broadcast room
• Photos
• Subscription
• Victoza® (liraglutide) press room
• Contact

• 
• Print

News

Reduction of the share capital and holding of own shares (22 June 2009) (22 June 2009)

Read the full announcement in PDF format

At Novo Nordisk's ordinary general meeting on 18 March 2009, it was decided to reduce the company's B share capital from DKK 526,512,800 to DKK 512,512,800 by cancellation of part of the company's portfolio of own B shares at a nominal value of DKK 14,000,000 divided into 14,000,000 B shares of DKK 1 each.

Further information:

Media:	Investors:
Outside North America:	Outside North America:
Elin K Hansen	Mads Veggerby Lausten
Tel: (+45) 4442 3450	Tel: (+45) 4443 7919
ekh@novonordisk.com	mlau@novonordisk.com
	Kasper Roseeuw Poulsen
	Tel: (+45) 4442 4471
	krop@novonordisk.com
In North America:	In North America:
Sean Clements	Hans Rommer
Tel: (+1) 609 514 8316	Tel: (+1) 609 919 7937
secl@novonordisk.com	hrmm@novonordisk.com

Company Announcement no 35 / 2009